CoChat

Midostaurin (PKC412) inhibits immunoglobulin E‐dependent activation and mediator release in human blood basophils and mast cells

Krauth, M.‐T., Mirkina, I., Herrmann, H., Baumgartner, C., Kneidinger, M., Valent, P. · 2009 · Clinical & Experimental Allergy
Cited by 89

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Summary: Background KIT tyrosine kinase inhibitors (TKI), such as nilotinib or midostaurin (PKC412), are increasingly used in clinical trials to counteract neoplastic cell growth in patients with aggressive mast cell (MC) disorders. However, these patients suffer not only from MC infiltration and consecutive organ damage but also from MC mediator‐related symptoms. Methods We examined the effects of three KIT TKI, imatinib, nilotinib, and midostaurin, on IgE‐dependent mediator release in normal human blood basophils and cultured cord blood cell‐derived MC, and on spontaneous histamine secretion in the MC leukaemia cell line HMC‐1 and the basophil cell line KU812. Results The multi‐kinase inhibitor midostaurin that interacts with KIT and protein kinase C was found to counteract anti‐IgE‐induced mediator release in blood basophils and cultured cord blood cell‐derived MC in all samples examined. By contrast, no effects of imatinib or nilotinib on histamine secretion in basophils or MC were found. The effects of midostaurin on histamine release were dose‐dependent and occurred at pharmacologic concentrations (IC 50 10‐100 n m). Midostaurin was also found to inhibit the IgE‐dependent up‐regulation of CD63 on cultured cord blood cell‐derived human MC, but did not inhibit IgE‐dependent up‐regulation of CD63 or CD203c in human blood basophils. Conclusion Midostaurin may be a beneficial drug in aggressive systemic mastocytosis not only because of its growth‐inhibitory effects but also because of its additional effects on activation and mediator release in MC and basophils.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2222.2009.03353.x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 89

Metadata

Authors
Krauth, M. ‐., Mirkina, I., Herrmann, H., Baumgartner, C., Kneidinger, M., & Valent, P.
Venue
Clinical & Experimental Allergy
Publisher
Wiley
Published
2009-10-21
Volume
39
Issue
11
Pages
1711-1720
ISSN
  • 0954-7894 (ISSN-L)
  • 1365-2222
OpenAlex
W2011637594
Cited by
89
References
3
FWCI
1.53
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Midostaurin (PKC412) inhibits immunoglobulin E‐dependent activation and mediator release in human blood basophils and mast cells. https://app.cochat.ai/papers/10.1111/j.1365-2222.2009.03353.x
The paper
Krauth, M. ‐., Mirkina, I., Herrmann, H., Baumgartner, C., Kneidinger, M., & Valent, P. (2009). Midostaurin (PKC412) inhibits immunoglobulin E‐dependent activation and mediator release in human blood basophils and mast cells. Clinical & Experimental Allergy. https://doi.org/10.1111/j.1365-2222.2009.03353.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.